AttendMe Owl Logo
AttendMe
Evidence Evolution
UrologyUrology

How This Evidence Evolved

Testicular Cancer Surveillance

Surveillance and risk-adapted treatment after orchiectomy

33.5

Timeline

Signal

Early observations and pilot data that first suggested a new direction

Proof

Landmark RCTs and pivotal trials that established the evidence base

Surveillance cohorts showed that observation after orchiectomy was safe. At Princess Margaret Hospital (PMH), 371 men with stage I NSGCT on active surveillance (1981-2005) had a 28% relapse rate at a median 6.3 years and 5-year disease-specific survival of 98.9-99.3%; relapse was 49.2-54.5% in high-risk patients (lymphovascular invasion and/or pure embryonal carcinoma) vs 14.2-18.7% in low-risk patients. For stage I seminoma, a pooled analysis of 638 surveillance patients from PMH, the Danish Testicular Cancer Study Group, the Royal Marsden and the Royal London hospitals found a 5-year relapse-free rate of 82.3%, with tumor size >4 cm and rete testis invasion predicting relapse. The MRC TE19/EORTC 30982 trial randomized 1477 stage I seminoma patients to adjuvant radiotherapy or one injection of carboplatin: 3-year relapse-free survival was 95.9% vs 94.8% (HR 1.28, 90% CI 0.85-1.93), and carboplatin caused less lethargy and time off work and fewer second testicular germ-cell tumors (5-year rate 0.54% vs 1.96%, p=0.04). Because most men never relapsed and only 3 PMH patients (0.8%) died from testis cancer, surveillance spared the majority from adjuvant treatment. An earlier prospective cohort enrolled 105 T1 NSGCT patients with normalized post-orchiectomy markers and no metastases, excluding pure choriocarcinoma or seminoma. At median 11.3 years, 27 (25.7%) relapsed and 3 (2.8%) died of disease.
Extension

Follow-up studies, subgroup analyses, and real-world validation

The Swedish and Norwegian Testicular Cancer Group (SWENOTECA) ran a prospective, population-based risk-adapted protocol for stage I NSGCT: patients with lymphovascular invasion (LVI) were recommended one course of adjuvant BEP, and those without LVI could choose surveillance or one course of BEP. Among 517 patients given one course of BEP, 5-year relapse was 3.2% with LVI and 1.6% without, and 5-year cause-specific survival was 100%. Imaging was also reduced to limit radiation in this young population. In MRC TE08 (stage I NSGCT), two CT scans (3 and 12 months) versus five gave intermediate-prognosis relapse in 0.8% vs 0.6% (difference 0.2%, 90% CI -1.2% to 1.6%). TRISST randomized 669 stage I seminoma patients to seven or three scans and to CT or MRI: three scans were statistically noninferior to seven, though stage ≥IIC relapse was more frequent (2.8% vs 0.3%), and MRI was noninferior to CT (0.6% vs 2.6%), with 5-year survival of 99%.
Now

Current standard of care and ongoing research directions

Surveillance evidence depends on histology, risk and follow-up. TRISST found 99% five-year survival with no tumour-related deaths in stage I seminoma, while the PMH nonseminoma cohort reported three testis-cancer deaths. SWENOTECA used LVI to guide one-course BEP or surveillance choices; its treated cohort does not define a universal high-risk population fraction. M371 was tested in 616 GCT patients and 258 controls: primary-diagnosis sensitivity was 90.1% and specificity 94.0%, with no expression in teratoma. The authors called for further validation. Questions include optimal CT/MRI schedules, patient anxiety and whether robotic RPLND can preserve function in selected patients.

Landmark Trials in This Story

MRC TE082007

Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group.

Intermediate- or poor-prognosis relapse at median 40 months: two CT scans (3, 12 months) 0.8% vs five 0.6% (difference 0.2%, 90% CI -1.2% to 1.6%)

J Clin OncolRandomized trial of two vs five CT scans in clinical stage I NSGCT on surveillance (247 vs 167 patients)
MRC TE19/EORTC 309822005

Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial.

Relapse-free rate at 2 years: radiotherapy 96.7% vs carboplatin 97.7%; at 3 years 95.9% vs 94.8% (HR 1.28, 90% CI 0.85-1.93, p=0.32)

LancetRandomised trial, 70 hospitals in 14 countries: radiotherapy (n=904) vs one injection of carboplatin (n=573)N=1,477
PMH Surveillance Cohort2011

Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.

Relapse at median 6.3 years: 28% overall; high-risk 49.2% vs low-risk 14.2% in the 1993-2005 cohort (p<0.0001); 5-year disease-specific survival 98.9-99.3%

Eur UrolSingle-centre active surveillance cohort, clinical stage I NSGCT, 1981-2005N=371
Warde 2002 pooled analysis2002

Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis.

Relapse-free rate at 5 years: 82.3% overall; tumor ≤4 cm vs >4 cm 87% vs 76% (P=.003); multivariate HR 2.0 (95% CI 1.3-3.2) for size >4 cm and 1.7 (1.1-2.6) for rete testis invasion

J Clin OncolPooled analysis of stage I seminoma surveillance cohorts (Princess Margaret Hospital, Danish Testicular Cancer Study Group, Royal Marsden Hospital, Royal London Hospital)N=638
Selected stage I NSGCT surveillance1998

Clinical stage I testis cancer: long-term outcome of patients on surveillance.

Relapse at median 11.3 years: 27/105 (25.7%); disease deaths 3/105 (2.8%)

Prospective surveillance cohortN=105
SWENOTECA2014Landmark

One course of adjuvant BEP in clinical stage I nonseminoma mature and expanded results from the SWENOTECA group

Relapse-free survival and cancer-specific survival

Annals of oncology : official journal of the European Society for Medical OncologyProspective population-based cohortN=517
TRISST2022Landmark

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

Six-year stage ≥IIC relapse incidence: MRI vs CT and three vs seven scans

Journal of clinical oncology : official journal of the American Society of Clinical OncologyRCT (2x2 factorial)N=669
M3712019

Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study.

Primary GCT diagnosis: sensitivity 90.1%, specificity 94.0%, ROC AUC 0.966. Teratoma did not express the marker. Relapse levels normalized upon remission; further validation required before clinical implementation.

Journal of clinical oncology : official journal of the American Society of Clinical OncologyProspective multicenter diagnostic biomarker study of 616 GCT patients and 258 male controls

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

What is the risk of relapse on surveillance for stage I testicular cancer?+
For stage I seminoma on surveillance, a pooled analysis of 638 patients found an actuarial 5-year relapse-free rate of 82.3%, and in TRISST 12% relapsed at a median follow-up of 72 months. For stage I NSGCT at Princess Margaret Hospital, relapse was 14.2-18.7% in low-risk patients and 49.2-54.5% in high-risk patients (lymphovascular invasion and/or pure embryonal carcinoma), with a median time to relapse of 7 months. Relapses are usually salvaged: TRISST reported 99% 5-year survival with no tumor-related deaths, and 0.8% of PMH patients died from testis cancer.
Does surveillance compromise survival compared to adjuvant treatment?+
Surveillance studies report high survival, but salvage is not universally successful. In the PMH cohort of 371 stage I nonseminoma patients, 28% relapsed and three died of testis cancer; estimated five-year disease-specific survival was 99.3% in the earlier cohort and 98.9% in the later cohort. TRISST reported 99% five-year survival with no tumor-related deaths in stage I seminoma. These studies do not prove survival equivalence across every adjuvant strategy.
How many CT scans are needed during testicular cancer surveillance?+
Surveillance protocols aim to minimize radiation exposure in this young patient population. In TRISST, three scans (at 6, 18, and 36 months) were statistically noninferior to seven for seminoma, although stage ≥IIC relapse was more frequent (2.8% vs 0.3%). TRISST also found MRI noninferior to CT (0.6% vs 2.6%) and concluded that MRI can be recommended to reduce irradiation.
What is the role of microRNA-371 (M371) as a tumor marker?+
Serum microRNA-371a-3p (the M371 test) was assessed in a prospective multicentre study of 616 patients with testicular germ cell tumors and 258 male controls: for primary GCT diagnosis, sensitivity was 90.1%, specificity 94.0% and area under the curve 0.966. It outperformed alpha-fetoprotein, beta-HCG and LDH, which had sensitivities below 50% in seminoma. All histologic subgroups except teratoma express the marker. In the 46 patients with relapse, levels were elevated and dropped to normal upon remission. The authors concluded that the test could be considered for clinical implementation after further validation.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026